Low-dose clofarabine in combination with a standard remission induction in patients aged 18–60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial

• Dominik Selleslag,
• Stefan Suciu,
• Giovanna Meloni,
• Petra Muus,
• Constantijn J.M. Halkes,
• Adriano Venditti,
• Safaa M. Ramadan,
• Hans Pruijt,
• Liv Meert,
• Marco Vignetti,
• Jean-Pierre Marie,
• Sébastian Wittnebel,
• Theo de Witte,
• Sergio Amadori,
• Roelof Willemze,
• Frédéric Baron

Affiliations

Dominik Selleslag

Department of Hematology AZ St-Jan Brugge-Oostende, Belgium

Stefan Suciu

EORTC Headquarters, Brussels, Belgium

Giovanna Meloni

Hematology, Sapienza University, Rome, Italy

Petra Muus

Department of Hematology, Radboud University, Medical Center, Nijmegen, the Netherlands

Constantijn J.M. Halkes

Department of Hematology, Leiden University Medical Center, the Netherlands

Adriano Venditti

Department of Hematology and of Biomedicine and Prevention, Tor Vergata University, Rome, Italy

Safaa M. Ramadan

EORTC Headquarters, Brussels, Belgium;Department of Hematology, Istituto Europeo di Oncologia, Milan, Italy

Hans Pruijt

Jeroen Bosch Medical Center, Den Bosch, the Netherlands

Liv Meert

EORTC Headquarters, Brussels, Belgium

Marco Vignetti

Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA), Rome, Italy

Jean-Pierre Marie

Department of Hematology, Hôpital Saint-Antoine, APHP, Paris, France

Sébastian Wittnebel

Department of Hematology, Institut Jules Bordet, ULB, Brussels, Belgium

Theo de Witte

Department of Tumorimmunology, Radboud University, Medical Center, Nijmegen, the Netherlands

Sergio Amadori

Department of Hematology and of Biomedicine and Prevention, Tor Vergata University, Rome, Italy

Roelof Willemze

Department of Hematology, Leiden University Medical Center, the Netherlands

Frédéric Baron

GIGA-I3-Hematology, University of Liège, Belgium